An interventional study of Acupuncture and Sham acupuncture in Obesity, Abdominal Obesity and PreDiabetes, sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Obesity, Abdominal with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Obesity, Abdominal · China.
Among the 19 studies in Obesity, Abdominal with a site in China, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 13th registered.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
Browse Obesity, Abdominal studies →6 of the 19 studies in Obesity, Abdominal with a site in China are open now. Recruiting first, the newest first:
Amway (China) R&D Center · Sites in China
Ages 30–65 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 9 more countries
Ages 18+
RenJi Hospital · Sites in China
Ages 18–65
Chinese University of Hong Kong · Sites in China
Ages 18–65
Zhejiang Provincial Tongde Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Median enrollment 120 across the 17 interventional studies, 211 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 137 studies on the registry; 37 are open to participants now.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences has 1 study filed under Obesity, Abdominal — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Abdominal with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07924956Amway (China) R&D CenterExplore the Weight Loss Effect of Amway "BODY TRIMMER" | 2027-02 |
| NCT06359418Guang'anmen Hospital of China Academy of Chinese Medical SciencesAcupuncture for Prediabetes With Combined Obesity | 2027-06-01 |
| NCT07759323Zhejiang Provincial Tongde HospitalPolygonatum Sibiricum Reduces Visceral Fat in Obese Adults | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Obesity, Abdominal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
This study's planned enrollment of 260 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Browse Obesity, Abdominal studies →Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 137 studies on the registry; 37 are open to participants now.
Compared within Obesity, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
Subjects are eligible to be included in the trial only if all of the following criteria apply:
Exclusion Criteria:
-
Subjects are excluded from the trial if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants in the acupuncture group will receive treatment that consists of 28 acupuncture sessions over a 12-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 8 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 x75mm; size 0.30 x 50mm; size 0.30 x 40mm) will be used. BaiHui(DU20), YinTang(EX-HN3), ShuaiGu(GB8), QuChi ( LI11), ZhongWan(RN12), XiaWan(RN10), TianShu(ST25), GuanYuan(RN4), FengLong(ST40), Daimai(GB26) and Fujie(SP14) were selected as acupoints protocol. At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity).
Device: Acupuncture
The participants in the sham acupuncture group will receive shallow needling at sham DU20, EX-HN3, GB8, LI11, RN12, RN10, ST25, RN4, ST40, GB26 and SP14. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-20 mm to the lateral of corresponding acupuncture and not above a meridian line. The Hwato brand disposable acupuncture needles(size 0.20 x25mm) will be inserted. At the same time, all participants will receive standardized lifestyle intervention counseling from randomization to end of whole study period, about once a month. Participants were advised to achieve a reduced-calorie diet (500-kcal deficit per day relative to the energy expenditure estimated at the time they underwent randomization) and increased physical activity (with 150 minutes per week of physical activity).
Device: Sham acupuncture
The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
The percentage change in body weight from baseline to week 12
The weight is measured by electronic scale with an accuracy of 0.1kg.
Time frame: week 12
The percentage change in waist circumference from baseline to week 12
The waist circumference is measured by a fiberglass tape measure with an accuracy of 0.1 centimeters.
Time frame: week 12
The percentage change in body weight compared to the baseline
The weight is measured by electronic scale with an accuracy of 0.1kg.
Time frame: week 4, week 8, week 16, week 20, week 24, week 28, week 32, week 36, week 52
The percentage change in waist circumference compared to the baseline
Waist circumference measurements are accurate to 0.1cm.
Time frame: week 4, week 8, week 16, week 20, week 24, week 28, week 32, week 36, week 52
Achievement of a reduction in body weight of 5% or more compared to the baseline
A 5% reduction is the weight loss target for obese patients recommended in most guidelines.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
Achievement of a reduction in body weight of 7% or more compared to the baseline
A 7% reduction is a weight loss target for obese patients with other metabolic diseases recommended in most guidelines.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
The change in body weight from baseline
The weight is measured by electronic scale with an accuracy of 0.1kg.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
The change in waist circumference from baseline
Waist circumference measurements are accurate to 0.1cm.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
The proportion of participants reverting to normoglycaemia
The determination is based on the results of blood glucose laboratory parameters.
Time frame: week 12, week 36, week 52
The proportion of participants developing diabetes
The determination is based on the results of blood glucose laboratory parameters.
Time frame: week 12, week 36, week 52
The change in 2hPG from baseline and percentage of patients who returned to normal
2hPG, 2-hour post-load Plasma Glucose, will be measured by oral glucose tolerance test, in mmol/L.
Time frame: week 12, week 36, week 52
The change in FPG from baseline and percentage of patients who returned to normal
FPG is fasting plasma glucose, the result will be reported in mmol/L.
Time frame: week 12, week 36, week 52
The change in HbA1c from baseline and percentage of patients who returned to normal
HbA1c is glycated haemoglobin, the result will be reported in percentage (%) units.
Time frame: week 12, week 36, week 52
The change in 1hPG from baseline and percentage of patients who returned to normal
1hPG, 1-hour post-load Plasma Glucose, will be measured by oral glucose tolerance test, in mmol/L.
Time frame: week 12, week 36, week 52
Changes in appetite VAS score from baseline
VAS=visual analogue scale; The VAS of appetite is a 100mm with two ends pointing to "none" and "difficult to control", respectively, and the subjects mark them on the online segment according to their perception. Appetite is quantitatively evaluated by measuring the distance from the left side of the segment to the marked point.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
The change in BMI from baseline
BMI=Body Mass Index, weight and height will be combined to report BMI in kg/m\^2.
Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52
The change in WHR from baseline
WHR=Waist-to-Hip Ratio, the ratio of waist to hip circumference, waist and hip circumference are accurate to 0.1cm.
Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52
The change in WHtR from baseline
WHtR=waist-to-Height Ratio, the ratio of waist circumference to height. Both are in cm units, accurate to 0.1cm.
Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52
The change in FINS from baseline
FINS is fasting insulin, the result will be reported in pmol/L.
Time frame: week 12, week 36, week 52
The change in HOMA-IR from baseline
HOMA, Homeostatic Model Assessment, is a mathematical model reflecting the interaction of glucose and insulin in different organs (including pancreas, liver, and surrounding tissues). lt was first proposed by Matthews in 1985. Insulin Resistance (HOMA-IR) will be evaluated by fasting plasma glucose (FPG) and fasting insulin (FlNS). The calculation method is HOMA-IR=FPG xFINS/22.5.
Time frame: week 12, week 36, week 52
The change in HOMA-β from baseline
HOMA, Homeostatic Model Assessment, is a mathematical model reflecting the interaction of glucose and insulin in different organs (including pancreas, liver, and surrounding tissues). lt was first proposed by Matthews in 1985. Islet β cell function (HOMA-β ) will be evaluated by fasting plasma glucose (FPG) and fasting insulin (FlNS). The calculation method is HOMA- β = 20 x FINS/ (FPG-3.5).
Time frame: week 12, week 36, week 52
The change in Serum total cholesterol from baseline
The Serum total cholesterol will be reported in mmol/L.
Time frame: week 12, week 36, week 52
The change in Triglyceride from baseline
The Triglyceride will be reported in mmol/L.
Time frame: week 12, week 36, week 52
The change in Low-Density Lipoprotein Cholesterol from baseline
The Low-Density Lipoprotein Cholesterol will be reported in mmol/L.
Time frame: week 12, week 36, week 52
The change in High-Density Lipoprotein Cholesterol from baseline
The High-Density Lipoprotein Cholesterol will be reported in mmol/L.
Time frame: week 12, week 36, week 52
The change in Serum Uric Acid from baseline
The Serum Uric Acid will be reported in μmol/L.
Time frame: week 12, week 36, week 52
The change in C-reactive protein from baseline
The C-reactive protein will be reported in mg/L.
Time frame: week 12, week 36, week 52
The change in blood pressure from baseline
Record the values of systolic blood pressure and diastolic blood pressure in mmHg.
Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 52
Changes of the score of the European five-dimensional Health scale (EQ-5D-5L) compared with the baseline.
EQ-5D-5L=European Quality of Life Five Dimension Five Level Scale Questionnaire. The questionnaire which is widely used to evaluate the quality of life of the general population is divided into two parts: EQ-5D health description system and EQ-VAS. The score was calculated by calculating formula according to the choices made by the subjects in the questionnaire.
Time frame: week 12, week 36
Changes of the PHQ-4 score from the baseline.
PHQ-4=patient health questionnaire-4. PHQ-4 consists of the first two items in PHQ-9 (PHQ-2) and the first two items in GAD-7 (GAD-2), including depression and anxiety. It is translated into Chinese by scholars and verified by scholars. It has good reliability and validity and is suitable for depression and anxiety screening.
Time frame: week 12, week 36
Expectance assessment
Participants will be asked the following question: What do you think will happen to your obesity and prediabetes in 3 months?
Time frame: baseline
Assessment of belief in acupuncture
Participants will be asked to answer "do you think acupuncture is helpful for obesity and prediabetes?" And three other related questions.
Time frame: baseline
Blinding assessment
Participants will be asked the following question: do you think you have received traditional acupuncture in the past weeks?
Time frame: week 12
Safety assessment
Adverse events and severe adverse events will be recorded in the case report form, whether related to interventions ol not.
Time frame: week 0 to week 52
Adherence assessment of acupuncture
Adherence will be assessed via counting treatment sessions. Those who complete over 80% treatment sessions will be defined as of good adherence.
Time frame: weeks 1 to week 12
Adherence assessment of life modification
Adherence will be assessed through dietary diaries and physical activity questionnaires.
Time frame: week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 52
Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.
Of 107 non-industry interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 27 months is above that.
Counting every sponsor, half of 117 studies reached it within 16 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences →